Gardasil 9 vaccine
BiologicalParticipants with a valid consent will be offered a three-dose Gardasil 9 series if eligible.
NCT Number: NCT06786429
Aim: The main goal of this quantitative epidemiological observational study is to determine the prevalence of Human Papilloma Virus (HPV) infection and Hepatitis B (Hep B) immunity amongst women of childbearing age. attending clinics at Mtshabezi Mission and Matobo clinic respectively, and assessing behavioral risk factors of high school students at these catchment areas that can put them at risk for developing cancer of the cervix and liver.
Question: Can screening for cancer, vaccination against Hep B and HPV, and cognitive behavior intervention help in preventing related cancers amongst these groups of participants?
Trial opening soon.
Get Notified13 year–50 year
All sexes
Interventional
Phase 4
Hypotheses:
Objectives
The objectives of this proposal are twofold:
1.1 Data collection, analysis, and interpretation to determine the burden of HPV infection; determine the HPV types that are prevalent in this community to assess the potential effectiveness of the available vaccine; assess the potential for developing a vaccine covering local Genotypes; determine the prevalence of immunity to Hep B, and depression prevalence among adult participants.1.2. Conduct a youth risk behavior screen to determine potential infection risk and mental health issues, and design intervention strategies.1.3 Disseminate preliminary findings after the first 6 months or year one and suggest intervention strategies that can be evaluated for effectiveness during the study period. Publish findings and scale project to other areas in Zimbabwe and internationally.1.4 Request collaboration with NIH/NCI/Global center/Behavioral health to strengthen research capabilities and service provision in this area.2. Intervention 2.1 Recruit 1140 consenting female participants attending prenatal, family planning, post-partum, and other clinics at these selected centers to perform a one-time comprehensive medical exam, pap smear (to detect abnormal cells, and HPV test (if eligible) to detect infection in the cervix); perform blood test to look for Hep. B. and cancer biomarkers' presence, perform a one-time fibro scan to assess the liver. 2.2 Administer the Youth Risk Behavior Screen (Centers for Disease Control and Prevention (CDC) to 1000 consenting students in the selected schools over a period of 5years to determine the types and significance of problem behavior and suggest appropriate interventions; Assess protective factors among boarders versus day scholars. offer the Gardasil 9 vaccine to 1000 eligible students with parental consent. 2.3 Refer participants with abnormal screens for further assessments and management, including behavioral health intervention as indicated. Assess potential for home visits, telehealth services, routine screening, and immunization to ease access to services. Create teen clinics at the school sites. Analyze data at three levels using the IBM Statistical Package for Social Sciences (SPSS) for significance testing and disseminate results. Solicit Ministry of Health and Childcare (MOHCC) buy-in for scaling to other Provinces.
Recommendations regarding women's health, i.e., screening for cervical cancer and vaccination against HPV and Hep B, depression, and Intimate Partner Violence will be guided by the findings of this study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
All students aged 13 years and older, enrolled at the selected Mtshabezi and Matopo High Schools in the Gwanda and Matobo Rural Districts during the five years of the project, are eligible to participate in the study.
Ability to understand and respond to questions on the Youth Risk Behavior Survey questionnaire and PHQ-9 scale.
Relevant history of HPV vaccine administration. Ability to obtain parental/guardian consent for participation.
Can understand and respond to the PHQ-9 and Edinburgh Postnatal Depression scales.
Must have a valid consent for participation in the study.
Exclusion criteria
Any potential participant who is unable to understand and respond to the questions being asked.
Participants with a valid consent will be offered a three-dose Gardasil 9 series if eligible.
Participants who do not demonstrate immunity to Hep B antibody marker in their blood, HBsAb and not HBsAg will be offered a three-dose series of Hep B. vaccine. A blood test will be done six months later to assess vaccine take i.e. immunity. Patients who demonstrate infection with Hep B virus will be referred to their doctor for further management.
Participants who demonstrate signs and symptoms of depression and/or anxiety will be offered individual behavioral management services. This consists of weekly individual sessions by a trained therapist for 8 weeks with option for referral for further management depending on the outcome of the intervention. The positive outcome consists of a change in presenting symptoms determined after administration of the youth risk behavior screen for high school students, and PHQ-9, and Edinburgh post-natal depression screen for women respectively.
Time frame: Baseline and 10 years post vaccination
Women will be screened for HPV infection at baseline, and post vaccine with Gardasil 9
Time frame: Baseline and six months to one year post vaccination.
Women will be screened for Hep B immunity before and after receiving a three-shot series of Hep B vaccine.
Time frame: Baseline assessment and 10 years post vaccination with Gardasil 9.
Patients will be assessed for malignancy on cervix
Time frame: Baseline and six months to one year post vaccination with Hep B.
Patients will have a fibro scan to assess condition of liver at initial visit and post vaccination with Hep B.
Time frame: Baseline and two to 12 months
Patients undergoing Cognitive Behavioral Therapy will be assessed for change in symptoms
Contact information is provided by the study sponsor or research team.
Eunice Dube, DSc.
CONTACT
Jill Koshiol, Ph. D.
CONTACT
Eunice Dube
Other
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers Among Women of Childbearing Age, and Young Adults in Zimbabwe in the Context of Mental Health: a Multimodal, Multifaceted Approach.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01931644
ADD/ADHD, Abnormalities, Multiple
Los Angeles, California, United States
View Trial DetailsNCT07253220
Adenocarcinoma, Blood-Borne Infections
View Trial DetailsNCT02779465
Adenocarcinoma, Blood-Borne Infections
View Trial DetailsNCT02366286
Adenocarcinoma, Blood-Borne Infections
Rochester, Minnesota, United States
View Trial Details